UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study

Jackson, Sarah E; Brown, Jamie; Tattan-Birch, Harry; Shahab, Lion; (2024) Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study. Addiction , 119 (7) pp. 1203-1210. 10.1111/add.16485. Green open access

[thumbnail of Brown_Addiction - 2024 - Jackson - Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England .pdf] Text
Brown_Addiction - 2024 - Jackson - Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England .pdf

Download (884kB)

Abstract

Background and aims: Varenicline is one of the most effective smoking cessation treatments. Its supply in England was disrupted in July 2021 due to nitrosamine impurities found by its supplier, Pfizer. This study measured the impact of this disruption on smoking cessation in England. // Design, setting and participants: The study used repeated cross-sectional surveys conducted monthly, from June 2018 to December 2022. Set in England, it comprised a total of 3024 adults who reported smoking during the past year and had made at least one serious attempt to quit in the past 6 months. // Measurements: Generalized additive models analyzed the association of the varenicline supply disruption with the trend in self-reported varenicline use in the most recent quit attempt. We used these results to estimate the population-level impact of the disruption on smoking cessation. // Findings: Before July 2021, the proportion of past 6-month quit attempts using varenicline was stable at approximately 3.9% [risk ratio (RR)trend = 1.034, 95% confidence interval (CI) = 0.823–1.298]. The trend in varenicline use has changed sharply since the supply disruption (RRΔtrend = 0.297, 95% CI = 0.120–0.738), with prevalence falling by 69.3% per year since; from 4.1% in June 2021 to 0.8% in December 2022. Convergently, National Health Service general practitioner prescribing data reported that just 0.1% of prescriptions for smoking cessation treatments in December 2022 were for varenicline. Assuming that varenicline does not return to the market, we estimate that this could result in ~8400 fewer people stopping smoking for at least 6 months, ~4200 fewer long-term ex-smokers and ~1890 more avoidable deaths each year. // Conclusions: In England, the disruption in supply of varenicline since 2021 has coincided with a substantial fall in the use of varenicline in attempts to quit smoking.

Type: Article
Title: Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/add.16485
Publisher version: https://doi.org/10.1111/add.16485
Language: English
Additional information: Copyright © 2024 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.This is an open access article under the terms of the Creative Commons Attribution License, https://creativecommons.org/licenses/by/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: Champix, Chantix, population study, quit attempts, smoking cessation, varenicline
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Behavioural Science and Health
URI: https://discovery.ucl.ac.uk/id/eprint/10188150
Downloads since deposit
3Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item